Echinacea: benefits, dosage, contraindications
Scientific name(s)
Echinacea angustifolia, Echinacea purpurea, Brauneria angustifolia, Echinacea pallida
Family or group:
Plants
Active ingredients:
Echinacoside
Cichoric acid
Caffeic acid
Alkylamides
Cynarine
Indications
Scoring methodology
EFSA approval.
Immune support ✪✪✪✪✪
Echinacea exerts an immunostimulant effect. Its effect on the immune system has been demonstrated in vitro and in vivo. In a randomized, double-blind, placebo-controlled trial, the total daily number of common cold symptoms was lower with echinacea than with placebo, and the difference was statistically significant after the third day. An increase in total leukocyte, monocyte, and neutrophil counts—but not lymphocytes—and an increase in neutrophil respiratory burst capacity were also observed, while erythrocyte superoxide dismutase units decreased during echinacea treatment.
Posologie
A comparison of the immunostimulatory effects of the medicinal herbs Echinacea, Ashwagandha and Brahmi.
Applications of the phytomedicine Echinacea purpurea (Purple Coneflower) in infectious diseases.
Medicinal Properties of Echinacea: A Critical Review
Immunopharmacological activity of Echinacea preparations following simulated digestion on murine macrophages and human peripheral blood mononuclear cells.
A proprietary extract from the echinacea plant (Echinacea purpurea) enhances systemic immune response during a common cold.
Enhancement of Innate and Adaptive Immune Functions by Multiple Echinacea Species
Common cold ✪✪✪✪✪
The reduction in the rate of ENT infections observed with echinacea as a daily supplement appears to be very effective in some cases, but is subject to a high degree of variability. Meta-analyses show a modest reduction in the risk of developing a common cold when taking various echinacea products. A large clinical study conducted with Echinaforce (A. Vogel) shows that adults who take 0.9 ml three times a day (providing 2,400 mg of echinacea per day) for 4 months, or 0.9 ml five times a day (4 g of echinacea per day) at the first sign of a cold, have fewer episodes and shorter duration of common cold than those who take a placebo. Overall, the data confirm a low-to-moderate efficacy. The EMA lists echinacea as an herbal medicinal product for the prevention and the short-term treatment of the common cold.
Posologie
Echinacea purpurea for prevention of experimental rhinovirus colds.
Randomized, double-blind, placebo-controlled trial of echinacea supplementation in air travelers.
Echinacea for the prevention and treatment of upper respiratory tract infections: A systematic review and meta-analysis.
Echinacea in the prevention of induced rhinovirus colds: a meta-analysis.
Use of a standardized extract from Echinacea angustifolia (Polinacea) for the prevention of respiratory tract infections.
Safety and Efficacy Profile of Echinacea purpurea to Prevent Common Cold Episodes: A Randomized, Double-Blind, Placebo-Controlled Trial.
Echinacea for preventing and treating the common cold.
Effects of echinacea on the frequency of upper respiratory tract symptoms: a randomized, double-blind, placebo-controlled trial.
Echinacea purpurea and mucosal immunity
European Union herbal monograph on Echinacea purpurea (L.) Moench, radix
Echinaforce and other Echinacea fresh plant preparations in the treatment of the common cold. A randomized, placebo-controlled, double-blind clinical trial.
An evaluation of Echinacea angustifolia in experimental rhinovirus infections.
A randomized controlled trial of the effect of fluid extract of Echinacea purpurea on the incidence and severity of colds and respiratory infections.
Evaluation of Echinacea for the prevention and treatment of the common cold: a meta-analysis
Efficacy and safety of Echinacea in treating upper respiratory tract infections in children: a randomized controlled trial.
Ineffectiveness of Echinacea for prevention of experimental rhinovirus colds.
Echinacea root extracts for the prevention of upper respiratory tract infections: a double-blind, placebo-controlled randomized trial.
Respiratory infections, Flu ✪✪✪✪✪
Echinacea may have antiviral activity against influenza virus, rhinoviruses, and herpes simplex viruses (HSV-1 and HSV-2). Preliminary research using viruses from nasal secretions suggests that Echinacea purpurea may inhibit enveloped viruses such as coronaviruses, influenza viruses, parainfluenza viruses, respiratory syncytial viruses, and metapneumoviruses. Clinically, a recent Cochrane systematic review indicates that the efficacy of echinacea may be superior to placebo for reducing the incidence of influenza, suggesting its potential usefulness as a preventive intervention. Another large study conducted in adults with respiratory infections shows that taking a daily 5-day combination containing 1100 to 2200 mg of echinacea, zinc, and vitamin C shortens recovery time; however, it had no major effect on symptom severity compared with placebo.
Posologie
Synergies
Use of a Standardized Extract From Echinacea Angustifolia (Polinacea) for the Prevention of Respiratory Tract Infections
Interventions for preventing influenza: An overview of Cochrane systematic reviews and a Bayesian network meta-analysis
Echinacea Purpurea For the Long-Term Prevention of Viral Respiratory Tract Infections During Covid-19 Pandemic: A Randomized, Open, Controlled, Exploratory Clinical Study
Effect of an Echinacea-Based Hot Drink Versus Oseltamivir in Influenza Treatment: A Randomized, Double-Blind, Double-Dummy, Multicenter, Noninferiority Clinical Trial
European Union herbal monograph on Echinacea purpurea (L.) Moench, herba recens
Pharyngitis ✪✪✪✪✪
Thanks to its antiviral and antibacterial action, Echinacea may be used in cases of pharyngitis and even bronchitis. An observational study examined the efficacy of an Echinacea and Sage lozenge in the treatment of pharyngitis. The study showed a significant reduction in viral load and symptoms, such as sore throat. However, there was no control group, which limits the validity of these results. The Echinacea/Sage lozenge contained 800 mg of hydroalcoholic extract of Echinacea purpurea (95% aerial parts and 5% root, Echinaforce®) and 378.5 mg of hydroalcoholic extract of Salvia officinalis leaves (drug extraction ratio 1:17).
Posologie
Synergies
Reduction of Viral Load in Patients with Acute Sore Throats: Results from an Observational Clinical Trial with Echinacea/Salvia Lozenges
European Union herbal monograph on Echinacea purpurea (L.) Moench, herba recens
Urinary tract infections ✪✪✪✪✪
Thanks to its immunostimulant and antibacterial properties, Echinacea is indicated for cystitis. ESCOP indicates it as an adjuvant and preventive therapy for recurrent infections of the urogenital tract.
Posologie
Gingivitis ✪✪✪✪✪
Preliminary clinical research shows that the use of a mouthwash containing echinacea, gotu kola and elderberry — 15 ml three times a day for 14 days — may prevent worsening of gingivitis compared with a placebo mouthwash, but it produces only minimal improvement in symptoms. The application of a periodontal patch containing echinacea, gotu kola and elderberry, either as a single dose or three times a day for 1 day then once a day for 2 days, appears to reduce some measures of inflammation and gingivitis at certain time points, but the effects are inconsistent.
Posologie
Synergies
Localized Reduction of Gingival Inflammation Using Site-Specific Therapy With a Topical Gingival Patch
A Phase II Trial of a Transmucosal Herbal Patch for the Treatment of Gingivitis
Vaginal infections ✪✪✪✪✪
Clinical results on the prevention of female urogenital infections (fungal infections, candidiasis, herpes) appear mixed, despite promising laboratory results.nnA one-year double-blind, placebo-controlled trial studied the effects of an extract of the plant and root of E. purpurea (Echinaforce 800 mg twice daily) on the incidence and severity of genital herpes outbreaks in 50 patients. The study did not show a statistically significant advantage over placebo after 6 months of treatment.nn
Posologie
Echinacea purpurea polysaccharide reduces the latency rate in herpes simplex virus type-1 infections
The Recurrent Vulvovaginal Candidiasis: Proposal of a Personalized Therapeutic Protocol
Does the extract of the plant Echinacea purpurea influence the clinical course of recurrent genital herpes?
Skin healing ✪✪✪✪✪
On wounds, Echinacea extracts appear to act by inhibiting bacterial proliferation and promoting healing by stimulating collagen synthesis.nnThe EMA recognizes echinacea as a traditional herbal medicinal product for the treatment of minor superficial wounds but also to relieve spots and pimples caused by mild acne.nnThe Commission E approves the external use of the herb E. purpurea for poorly healing wounds and chronic ulcerations.nn
Posologie
Properties
Immunostimulant




The immunostimulatory properties of Echinacea appear to target both non-specific and specific immune function. The effects non-specific include increased macrophage proliferation and phagocytosis, as well as the secretion of interferon beta-2, tumor necrosis factor (TNF), and interleukin-1 (IL-1). The constituents of Echinacea thought to be involved in stimulating non-specific immune responses include high-molecular-weight polysaccharides such as heteroxylan and arabinogalactan, and lower-molecular-weight compounds such as alkylamides, chicoric acid, and echinacosides. Specific immune responses specific include activation of other components of the complement pathway and increased levels and activity of T lymphocytes, neutrophils, and natural killer (NK) cells. These effects may be due to the polysaccharides present in Echinacea.
Usages associés
Antiviral




Echinacea may have antiviral activity against influenza virus, vesicular stomatitis virus, and herpes simplex viruses (HSV-1 and HSV-2). Preliminary research using viruses from nasal secretions suggests that Echinacea purpurea may inhibit enveloped viruses such as coronaviruses, influenza viruses, parainfluenza viruses, respiratory syncytial viruses, and metapneumoviruses. Echinacea enhances resistance to upper respiratory tract infections caused by rhinoviruses. It also increases resistance to infections during treatments of cutaneous warts. Caffeic acid and chicoric acid have in vitro antiviral activity (lasting 24 to 48 hours).
Usages associés
Antibacterial




Echinacoside has a dose-dependent antibacterial inhibitory effect in vitro on the growth of certain microbes. This activity is more specific against Staphylococcus aureus, Streptococcus pyogenes, Escherichia coli, and the acne pathogen Propionibacterium acnes. An anti-adhesion activity to intestinal cells has also been observed against the pathogen Campylobacter jejuni, which is responsible for diarrhea.
Usages associés
The potential use of Echinacea in acne: control of Propionibacterium acnes growth and inflammation
Investigations into the antiadhesive activity of herbal extracts against Campylobacter jejuni
Antifungal




Activity has been demonstrated against Candida albicans. It is corroborated by clinical results, particularly in the prevention of female urogenital infections. The polyacetylenic compounds of echinacea, including ketoalkenes and ketoalkynes, appear to be responsible for the antifungal activity, notably against the yeast Candida, including Candida albicans.nn
Usages associés
The Recurrent Vulvovaginal Candidiasis: Proposal of a Personalized Therapeutic Protocol
Polysaccharides isolated from plant cell cultures of Echinacea purpurea enhance the resistance of immunosuppressed mice against systemic infections with Candida albicans and Listeria monocytogenes
Anti-inflammatory




Studies on echinacea have shown that alcohol extracts, from the three species (E. angustifolia, E. purpurea, and E. pallida), have anti-inflammatory properties. The active compounds responsible are:nn- Alkamides: inhibit the enzyme iNOS, which plays a role in the production of nitric oxide, a mediator of inflammation.nn- Caffeic Acid: increases the activity of arginase, an enzyme that helps reduce inflammation.nn- Alkylamides from the roots of E. purpurea: partially inhibit the enzymes COX-1 and COX-2, which are involved in the production of prostaglandins, compounds that contribute to inflammation and pain.nn
Endogenous levels of Echinacea alkylamides and ketones are important contributors to the inhibition of prostaglandin E2 and nitric oxide production in cultured macrophages
Wound healing




Animal research suggests that Echinacea extracts can accelerate wound healing, improve epithelialization, and reduce inflammation. The constituent echinacoside appears to protect type III collagen from damage caused by free radicals, and may have activity against bacterial hyaluronidase, which is necessary for bacteria to spread through the skin and mucous membranes. Several uncontrolled clinical studies support the topical use of Echinacea to improve wound healing. A trial involving 4,598 people studied the effects of a preparation made from the juice of the aerial parts of E. purpurea on various wounds, burns, skin infections, and inflammatory skin conditions. Topical application of Echinacea produced an overall success rate of 85%, and the main component responsible for the improvement in wound healing appears to be echinacoside as noted above.
Usages associés
Safe dosage
Adults 18 years and older: 900 mg - 4000 mg (powder)
The recommended daily dose for an adult is 900 mg (equivalent raw plant material).nnIn studies, doses up to 4 g per day have been used.nnIn dry extract: 360 mg/daynnIn mother tincture (MT): 15 to 30 drops, 3 times per day.nn
Children aged 4 to 18 years: 900 mL - 2000 mL (powder)
Dosage according to the manufacturer; up to 2 g equivalent fresh plant per day in the acute phase.nnIn mother tincture (MT) from 12 years of age: 1 drop/kg/day, in three doses.nn
Interactions
Médicaments
Cyclophosphamide: moderate interaction
Echinacea appears to increase the immunostimulatory effect of low-dose cyclophosphamide, which may affect autoimmune diseases.
Cyclosporine: moderate interaction
Echinacea may inhibit the effect of cyclosporine.
Immunosuppressant: moderate interaction
Theoretically, echinacea may interfere with immunosuppressive therapy because of its immunostimulant activity. Immunosuppressant drugs include azathioprine, basiliximab, cyclosporine, daclizumab, muromonab-CD3, mycophenolate, tacrolimus, sirolimus, prednisone, and other corticosteroids.
Plantes ou autres actifs
Echinacea: moderate interaction
Echinacea appears to increase plasma caffeine concentrations by 30%. This is likely due to inhibition of cytochrome P450 1A2 (CYP1A2) by echinacea.
Precautions
Pregnant women: use with caution
There is preliminary evidence that women may safely use echinacea (Echinacea purpurea or Echinacea angustifolia) at doses of 250 mg to 1000 mg per day, or as tinctures up to 30 drops per day for 5 to 7 days during the first trimester of pregnancy without harming the fetus. nnPregnant women are advised to remain cautious and consult their physician.nn
Breastfeeding women: use with caution
No data available.nn
Autoimmune diseases: use with caution
Echinacea appears to stimulate immune function. Theoretically, it could exacerbate autoimmune diseases by increasing disease activity. Therefore, avoid or use echinacea with caution in people with autoimmune diseases such as multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, or other conditions.nn
Atopy: avoid
People with atopy (a genetic tendency toward allergic conditions) may be more likely to have an allergic reaction when taking echinacea. Case reports describe several instances of allergic reactions to echinacea consistent with IgE-mediated hypersensitivity. 34% of reactions were observed in patients with atopy.
Hemochromatosis: use with caution
In cases of hemochromatosis, echinacea use should be monitored.
Oral: root, aerial parts
1500 - 2400 mg
1 - month
Adults
standardized extract, dry extract
